Lassa fever is one of the WHO R&D Blueprint priority diseases. This hemorrhagic fever is endemic in Benin, Ghana, Guinea, Liberia, Mali, Sierra Leone, Togo and Nigeria. Case fatality rates vary between 1 and 15%, as early diagnosis is critical with many viral diseases. A Platform clinical trial testing several therapeutic options is underway by the INTEGRATE Consortium in Nigeria, , the country reporting the highest number of cases annually. This work is being coordinated by Prof. Sylvanus. A. Okogbenin, leader of PANTHER’s Lassa Hub.
PANTHER with its partners (ALIMA and BNITM) will start exploring the needs and prepare one site in Guinea (Nzerekore or Gueckedou), in Liberia (Phebe hospital) and one other site in Nigeria (Abakaliki) whilst setting-up a mobile team to manage the sporadic and scattered cases in Benin.
For more information, see Lassa fever (who.int) and Lassa Fever – Africa CDC